Development of an effective vaccine against HIV-1 will likely require the induction of a broad array of immune responses, including virus-specific CTLs and neutralizing antibodies. One promising vaccine approach involves live recombinant canarypox (CP)-based vectors (ALVAC) containing multiple HIV-1 genes. In phase I clinical trials in HIV-1-seronegative volunteers, the cumulative rate of detection of HIV-1-specific CTLs has been as high as 60-70%. In the present study, the factors associated with CTL responsiveness were evaluated in a subset of vaccinees immunized with a CP vector expressing portions of the gag, pro, and env genes of HIV-1 (ALVAC-HIV). CTL responses were detected in one of seven examined. While the responding individual had both CD4 1 and CD8 1 CTLs directed at multiple HIV-1 antigens, this response was not detectable 1 year after the last vaccination. In-depth characterization of "CTL nonresponders" showed that nonresponsiveness was not associated with defects in antigen processing or presentation. A generalized defect in CTL responsiveness was ruled out by parallel assays to detect CMV-specific CTLs from these same volunteers. Furthermore, HIV-1-specific memory CTLs were not detectable by peptide stimulation or by a novel technique for flow cytometric visualization of Gag epitope-specific T lymphocytes while HIV-1-seropositive donors frequently had 0.1-3% of CD8 1 cells stain positively for this epitope (SLYNTVATL). Taken together, these results suggest that the lack of detectable HIV-1 CTLs in these volunteers was not due to classic MHClinked nonresponsiveness.
INTRODUCTION
A LT H O U G H TH ER E H A V E B EEN tremendous advances in antiretroviral therapy, the best hope for combating the AIDS epidem ic on a global scale remains the development of a vaccine. It is widely accepted that an effective AIDS vaccine will stimulate multiple types of immune responses against several proteins of HIV-1. A prim ary focus has been on developing live viral vectors that will invoke strong and persistent cytotoxic T lymphocyte (CTL) responses in vaccinated individuals. CD8 1 CTLs have been previously shown to play a key role in host defense against other human pathogenic viruses such as influenza and cytomegaloviru s (CMV). [1] [2] [3] [4] [5] [6] [7] The importance of virus-specific CTLs in HIV-1 and SIV infection is illustrated by several observations. CD8 1 CTLs are readily detectable early after acute infection, coincident with the resolution of high levels of initial viremia. [8] [9] [10] [11] In addition, Ogg et al. have demonstrated an inverse correlation between HIV-1-specifi c CTL frequency and plasma RNA viral load. 12 The presence of Env-specific CTLs early after infection has been correlated with lower viral load and delayed disease progression. 13 Furthermore, HIV-1-infected individuals who fail to progress to AIDS (long-term nonprogressors) have persistently high levels of HIV-1-specific CTLs, and decline in this antiviral response coincides with disease progression. 14-1 9 Moreover, several investigators have show n that in infected individuals in whom high-frequency oligoclonal CTL responses to specific epitopes can be detected, selection for mutations within those epitopes occurs and may be associated with disease progression. 20 ,21 Finally, virus-specific CTLs have been identified in repeatedly exposed but un-infected individuals. [22] [23] [24] For exam ple, in a study by Pinto et al. 22 CD8 1 -restricted Env CTLs were detected in 35% of health care workers who were exposed to HIV-infected blood and Rowland Jones et al. 23 reported HIV-1-specifi c CTLs in 83% of HLA B35-positive Gambian female prostitutes tested. Taken together, these results provide strong support for the notion that induction of CTLs is an important vaccine goal.
Initial phase I trials of candidate AIDS vaccines involved recom binant form s of the HIV-1 Env protein. While these vaccines elicited strong humoral responses, primarily CD4
1 CTL responses were detected. [25] [26] [27] [28] [29] [30] Subsequent trials focused on recom binant pox viral vectors. In initial human studies, a subset of immunized volunteers who received a vaccinia virus vector carrying the HIV-1 env gene, followed by a subunit boost with rgp120, developed high levels of CD8 1 CTLs specific for the Env protein. 31-3 3 Despite the capacity of vaccinia-based vaccines to elicit strong CTL responses in vaccinia-naive hum ans, safety issues related to the potential dangers of vaccinia infection in immunocompromised individuals and limitations in vaccinating persons previously exposed to vaccinia (e.g., smallpox vaccination) have shifted the focus to avian poxvirus vectors that do not replicate in human cells. Canarypox virus vectors have been shown to be highly effective vaccine vectors for a num ber of animal pathogens including feline leukemia virus, 34 rabies virus, 35, 36 and canine distemper virus. 37, 38 Canarypoxbased vaccines have been shown to elicit CD8 1 CTLs in animal models such as Japanese encephalitis virus infection in mice. 39 Canarypox-base d vaccines against CMV are currently under investigation. 40 There have been encouraging reports of the detection of CD8 1 CTLs in individuals receiving experimental recombinant canarypox virus-based AIDS vaccines expressing the HIV-1 env gene. 41 -45 The new generation of canarypox vectors expresses multiple HIV-1 genes including portions of gag, pro, env, and nef. Phase I trials testing the safety and immunogenicity of these vectors are ongoing.
The canarypox viral vectors tested thus far have proven safe in human volunteers. However, the goal of achieving strong and persistent CTL responses in 100% of vaccinated individuals has not yet been achieved. This study describes an algorithm for the study of CTL responsiveness in trials of candidate AIDS vaccines and examines possible factors that might contribute to the individual variation in CTL responses observed.
MATERIALS AND METHODS

Vaccines
The vaccine tested was a live recom binant canarypox virus carrying the genes encoding HIV-1 M N gp120, the transmembrane portion of HIV-1 LA I gp41, full-length HIV-1 LA I Gag, and HIV-1 LA I protease (ALVAC-HIV; vCP205) and, as a placebo control, a live recombinant canarypox virus carrying the rabies glycoprotein G gene (ALVAC-RG; vCP65). In these vectors, foreign gene expression is under the transcriptional control of the vaccinia H6 early/late promoter. The ALVAC-HIV and ALVAC-RG vectors were produced by Pasteur-Merie ux Serums et Vaccins (Marnes-la-Coquette , France). Some volunteers were boosted with purified recombinant HIV-1 S F -2 gp120 in MF59 adjuvant (Chiron [Biocene], Emeryville, CA). The MF59 adjuvant is form ulated as an emulsion containing polysorbate 89, sorbitan trioleate, and squalene.
Study design
HIV-1 Gag-, Pro-, and Env-specific CTLs were measured in nine HIV-1-serone gative adult volunteers participating in a phase I HIV-1 vaccine trial (022) organized by the National Institute of Allergy and Infectious Diseases (NIAID)-sponsored AIDS Vaccine Evaluation Group (AVEG). Volunteers were divided into groups based on vaccination schedule. The vaccination schedule is described in Table 1 . Blood was collected in tubes containing the preservative acid-citrate-dextrose (ACD). Peripheral blood mononuclear cells (PBMCs) were always analyzed for CTL activity prior to vaccination (baseline) and CARRUTH ET AL. 1022 roughly 2 weeks postvaccination and, depending on various factors, at weeks 0, 6, 14, 26, 41, 54, and 104 postvaccination. This study was performed in a blinded fashion.
Expansion of HIV-1-specific CTLs
PBMCs were plated in 24-well plates at 10 7 cells/well in culture medium consisting of RPMI (GIBCO-BRL, Gaithersburg, MD) supplemented with 10% heat-inactivated fetal calf serum (Summit Biotechnology, Boulder, CO), penicillin (50 U/ml), streptomycin (50 m g/ml), and 4 mM L-glutamine (GIBCO-BRL).
Cultures also included stimulator cells that were prepared by infecting autologous Epstein-Barr virus (EBV)-transformed B lymphoblastoid cell lines (B-LCLs) at a multiplicity of infection (MOI) of 5:1 with a WR strain vaccinia virus vector expressing HIV-1 M N gp120, the transmembrane portion of HIV-1 LA I gp41, full-length HIV-1 LA I Gag, and HIV-1 LA I protease. This vector (vP1291) is referred to as vac-gag-pro-env. Stimulating cells were incubated for 16 hr, washed, and resuspended at a concentration of 10 6 cells/ml in culture medium containing psoralen (49 -aminomethyl-4,5 9 ,8-trimethylpsoralen hydrochloride, 10 m g/ml;
HRI Associates, Berkeley, CA). After a 10-min incubation at room temperature, the cells were transferred to a sterile petri dish and irradiated using a long-wave UV light box for 5 min with occasional mixing. PBMCs were plated at a concentration of 5 3 10 6 cells/ml with washed, psoralen-treated stimulator cells at a PBMC-to-stimulator ratio of 10:1. On day 4, recombinant interleukin 2 (IL-2) was added to a final concentration of 100 U/ml. Cultures were subsequently fed with culture medium containing IL-2 (100 U/ml) as needed. For stimulation using epitopic peptides, autologous B-LCLs were pulsed with peptide at a final concentration of 10 m M for 1 hr at 25°C, treated with psoralen and UV light, and plated with fresh PBMCs as described above. For experiments detecting CMV-specific CTLs, a vaccinia vector expressing pp65 of CMV (vac-pp65, a gift from D. Diamond, Beckman Research, Duarte, CA) was used for infection of B-LCL.
Detection of CTL responses
After a single 10-to 14-day in vitro stimulation, antigen-specific CTL activity was determined as previously described. 46 Target B-LCLs were pulsed with synthetic peptides (10 m M final concentration), or were mock infected, infected with wildtype vaccinia virus (L-var), or with vaccinia vectors expressing gag-pro and env (vac-gag-pro-env ; vP1291) as described above. For experiments detecting CMV-specific CTLs, a vaccinia vector encoding the CMV protein pp65 (vac-pp65) was used to infect target cells. Background lysis by vaccinia-and EBV-specific CTLs was greatly reduced in all cultures by the addition of a 30-to 50-fold excess of cold autologous vacciniainfected B-LCLs. The standard error (SE) of the percent specific lysis was calculated as previously described, 31 and was generally less than 5%. The phenotype of the responding cells was determined by selective depletion of T cell subpopulations with anti-CD4 or -CD8 monoclonal antibodies conjugated to magnetic beads (Dynal, Lake Success, NY).
CMV antibody ELISAs
Serum samples from bleed dates corresponding to CMV-specific CTL assays were tested by SmithKline Beecham Clinical Laboratories (Philadelphia, PA) for levels of CMV-specific IgG. Enzyme immunoassay (EIA) values $ 1.10 are considered positive for CMV-specific antibodies and suggest a current or past infection.
Peptides and T cell clones
HTLV-I Tax 11-19 (LLFGYPVYV), and HIV-1 p17 gag 77-85 (SLYNTVATL) and gp120 37-46 (TVYYGVPVWK), were synthesized and purified by high-perform ance liquid chromatography (HPLC) at the Colorado State University Macromolecular Resources (Fort Collins, CO). Composition of the peptides was confirmed by mass spectrometry.
The HLA-A2-restricted HIV-1 Gag 77-85-specific CD8 1 CTL clone 10830 was generously provided by C. Brander (Harvard University), and has been described elsewhere. 47 The HLA-A3-restricted CD8 1 CTL clone A42.46 recognizes the Env 37-46 peptide TVYYGVPVWK and has been previously described. 31 
Cloning and expression of A2/IgG
Using an oligonuc leotide-directed polym erase chain reaction (PCR), we introduc ed 59 MluI and 39 NotI sites (sites underlin ed) into the extracellular dom ain (a 1 -a 3 ) of HLA-A2 cDNA (kindly provided by P.F. Robbins, NCI, NIH, Bethesda, MD) using the follow ing prim er pair: 59 GAT-ACGCGTTGG-GCTCTCACTCCATGAG and 59 CAGTC-GATGCGGCCGCCCATCTCAGGGTGAGGGGCT. After PCR amplification the a 1 -a 3 region of HLA-A2 was sequenced and directionally cloned in exchange for H-2K b into the previous ly describe d pX/Ig vector. 48 Subsequently, the HLA-A2/Ig chim era and the human a 2 -microglob ulin gene were cotransfected by electrop oration into J558L cells. Transfecta nts were screened for secretio n of the chim eric protein enzym e-linked immunosorbe nt assay (ELISA) as previous ly describe d. 48 ELISA plates were coated with BB7.2, an antibody specific for peptide-loaded conform ations of HLA-A2, or with a goat anti-m ouse IgG-Fc antibody 
Flow cytometric analysis
Murine antibodies to human CD8 (Sigma, St. Louis, MO) and to CD4 (Becton Dickinson, San Jose, CA), both conjugated to phycoerythrin (PE), were used to detect the relevant cell surface molecules. HLA-A2/Ig bound to the cell surface was detected using goat anti-m ouse IgG 1 -PE or a goat anti-mouse IgG 1 -TC (Caltag, San Francisco, CA). Lymphocytes were gated by forward and side scatter. Gated events (1 3 10 5 ) were analyzed using CellQuest software (Becton Dickinson).
RESULTS
Characterization of HIV-1-specific immune responses in vaccine recipients
The purpose of this study was to exam ine the factors that determine whether vaccinated HIV-1-negative humans develop strong HIV-1-specific CTL responses to canarypox-based AIDS vaccines. The CTL assay used in this trial involves a single antigen-specific stimulation and has been described in detail elsewhere. 46 To gauge the sensitivity of the CTL assay, identical assays were routinely performed on PBMCs from HIV-1-seropos itive individuals. While vaccination may not necessarily induce a level of CTL activity comparable to that seen in natural infection, CTL responses of this magnitude may be necessary to prevent disseminated infection. 49 HIV-1-specific CTLs were detected in nearly all seropositive donors tested, regardless of the stage of disease as assessed by CD4 1 cell count. 46, 50 A representative assay shown in Fig. 1 illustrates that the assay used readily detects CTLs generated during natural infection. As an additional control, nonvaccinated, HIV-1-seroneg ative individuals were tested using this assay. In this case, no HIV-1-specific CTLs were detected. Furthermore, in more than 70 samples obtained prior to vaccination and in samples from recipients of placebo vaccine preparations, no false-positive HIV-1-specific CTL responses were detected.
Therefore, this assay has the sensitivity to readily detect the levels of CTL activity seen in infected individuals and has an extremely low-false positive rate.
CTL responses to the ALVAC-HIV vaccine were evaluated in a randomized, placebo-controlled , double blind trial designed to assess the safety and immunogenic ity of this candidate AIDS vaccine. The vaccine preparation is described in detail in Materials and Methods. Briefly, the ALVAC-HIV vaccine is a live recombinant canarypox-based vector expressing the HIV-1 M N env gene and the HIV-1 IIIb gag-pro gene. Volunteers were healthy HIV-1-seroneg ative adults, 18-60 years of age. The vaccination schedule and volunteer characteristics are given in Table 1 . Longitudinal analysis of CTL activity in vaccine recipients is presented in Fig. 2A . Each line represents the HIV-1-specific CTL activity of an individual volunteer over time. Seven volunteers received two to four vaccinations with ALVAC-HIV, but only one (8MU) had a detectable HIV-1-specific CTL response during the course of the study. For this volunteer, antibody depletion and single-cell cloning experiments showed that the CTL activity was directed against epitopes in Gag and Env and was mediated by CD8 1 T cells. High levels of Gag-and Env-specific CTL activity were detected even after depletion of CD4 1 cells ( . The percent HIV-1-specific lysis value at a 50:1 E:T ratio was calculated as the percent specific lysis of targets infected with vac-gag-pro-env minus the percent specific lysis of targets infected with the control vac vector. The arrows indicate vaccinations with ALVAC-HIV (large arrows) or subunit boosting with rgp120 (small arrows). See Table 1 for details of the immunization schedules for individual donors. (B) CTL response of vaccine volunteer 8MU at week 54. PBMCs were stimulated with autologous B-LCLs infected with vac-gag-pro-env. After 10 days, responding cells were mixed with anti-CD4-coa ted beads. The remaining CD8 1 cells were tested in a CTL assay with autologous B-LCLs infected with control vaccinia vectors (vac) or vaccinia vectors expressing individual HIV-1 genes (vac-env, vac-gag, vac-pro). A positive HIV-1-specifi c response is a percent specific lysis value that was 10% or more above the percent specific lysis of the mock or wild-type vaccinia-infected targets at two or more E:T ratios.
A B als using canarypox-HIV -1 vectors, only a subset of volunteers made detectable HIV-1-specific CTLs during the course of the trial (data not shown). 41 The cumulative rate of HIV-1-specific CTL responsiveness from all 60 trial participants has been reported as 60% (K. Weinhold, personal communication, 1998). It is important to note that this study examines 7 of 60 total trial volunteers. Of the seven described in this study, som e may have had vaccine doses and vaccination schedules that subsequent studies have determined to be suboptimal. These volunteers were retested approximately 1 year after the last vaccination, and none had detectable CTL activity ( Fig. 2A) . Taken together, these results demonstrate that recombinant canarypoxbased vaccine regim ens can elicit CTLs in some recipients. However, as is the case with all other HIV-1 vaccines tested to date in our laboratory, the CTL responses elicited by this vaccine regim en were not universal or durable.
An algorithm (shown in Fig. 3 
protein to elicit an antibody response. In one volunteer (8N1), who received only two ALVAC-HIV immunizations without an rgp120 boost, no antibody response was detected. In this individual, there remains the form al possibility that the vaccine vector was unable to infect cells in the recipient. However, in vitro studies showed that when B-LCLs from this volunteer were infected with the ALVAC-HIV vector and tested for protein expression by Western blot, the appropriate HIV-1 antigens were expressed, albeit at lower levels than by cells infected with comparable vaccinia vectors (data not shown).
Memory CTL response to other viral infections
The four vaccinees who completed the trial and had a positive antibody response (8MU, 8MV, 8MW, and 8N5) were studied further in an effort to understand why they failed to mount a detectable HIV-1-specific CTL response even though HIV-1 antigens were clearly expressed after immunization . We first asked whether memory CTLs to other viral pathogens could be detected in trial volunteers using the same in vitro stimulation and CTL assay procedure. To answer this question, vaccinated volunteers were tested for memory CTLs to cytomegaloviru s (CMV), using a protocol identical to that used to detect HIV-1-specific CTLs. CMV pp65 is a protein that is recognized by a majority of CMV-seropositive individuals (D. Diamond, personal communicatio n, 1998). A vaccinia vector expressing CMV pp65 (vac-pp65) was used to infect B-LCLs from vaccine volunteers. After a 16-hr incubation, these cells were treated with psoralen and UV light and then mixed with fresh PBMCs from vaccinees. After in vitro culture for 10-14 days, cultures were assayed for CMV-specific CTL activity. Serum sam ples from the same bleed were also analyzed for CMV-specific antibody to establish prior exposure to CMV. The results in Table 2 show that for two of the four vaccinees in this trial, and two additional vaccinees in other canarypox-HIV -1 vaccine trial, there was a perfect correlation between the presence of CMV-specific CTL activity and CMV seropositivity, consistent with current or prior exposure to CMV. Thus, the sam e overall strategy used here to detect HIV-1-specifi c CTLs successfully detects memory CTLs specific for other viruses in individuals who have been exposed to those viruses. In addition, because three of the four volunteers tested had been previously exposed to vaccinia (through smallpox vaccination) and because the stimulation procedure involved vaccinia, a vacciniaspecific CTL response could be detected in all of these individual (data not shown). To ensure that HIV-1-specific CTLs could be detected above the background of vaccinia-specific CTLs, an excess of 30-to 50-fold wild-type vaccinia-infected cold targets was routinely added to the CTL assays. Omission of cold targets in CTL assays invariably revealed the presence of high levels of vaccinia-specific CTLs, again indicating that the general procedure used here for measuring CTL responses was able to identify memory CTLs to other viral antigens (data not shown). Taken together, these results suggest that the failure of some vaccinees to mount an HIV-1-specifi c CTL response was not due to problem s with the CTL assay or to a global defect in CTL responses to viral antigens. 59 The small number of volunteers studied in phase I trials makes it difficult to evaluate such associations through standard statistical approaches. Therefore an alternative approach was used to determine whether the failure of some vaccinees to generate CTL responses was due to class I MHC-linked nonresponsiveness. The HLA-A and -B alleles expressed by volunteers are listed in Table 1 . All of the volunteers studied expressed at least one MHC class I allele nominally known to present previously defined HIV-1 Gag or Env epitopes. 60 In this case, the absence of CTL responses might reflect the expression of allelic variants that fail to present the relevant epitope. Alternatively, nonresponsiveness could result from defects in antigen processing or in the T cell receptor repertoire or from failure of the vaccine to stimulate a sufficient number of epitope-specific CTL precursors (refer to algorithm in Fig. 3) .
Analysis of MHC-linked nonresponsiveness
To ensure that the class I alleles expressed by the nonresponders actually had the capacity to present the relevant epitopes, B-LCLs from these volunteers were pulsed with the appropriate epitopic peptides, and used as targets in CTL assays with epitope-specific CD8 1 T cell clones isolated from seropositive individuals or seronegative vaccinees with strong HIV-1-specific CTL responses. Results presented in Fig. 4 demonstrated that nonresponder B-LCLs expressing the correct MHC allele were able to present epitopic peptides to HIV-1-specifi c c 8HM and 8HB were vaccinated in another canarypox trial.
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CTL clones. When B-LCLs from HLA-A3 1 CTL responder 8MU and from CTL nonresponders 8MV, 8N1, and 8MW were pulsed with an A3-restricted Env peptide, they were all readily lysed by the previously described A3-restricted, Env-specific clone A42.46 (Fig. 4A) . Similar results were obtained when peptide-pulsed volunteer B-LCLs were used as targets in CTL assays with a bulk population of stimulated PBMCs from MHCmatched, HIV-1-infected individuals (data not shown). Likewise, when B-LCLs from HLA-A2 1 CTL nonresponders 8MV, 8MW, and 8N5 were pulsed with an immunodominant A2-restricted Gag peptide, they were efficiently lysed by the HLA-A2-restricted, Gag-specific clone 10830, obtained from an HIV-1-infected donor (Fig. 4B) . These results indicate that the lack of CTL responsiveness in the individual was not due to expression of a nonpresenting allelic variant of an MHC molecule known to present HIV-1-derived products.
Antigen processing and presentation of HIV-1 antigens
Another possible explanation for CTL nonresponsivenes s involves a defect in antigen processing. To rule out this possibility, B-LCLs from vaccinees were infected with vaccinia constructs expressing the appropriate HIV-1 antigens and used as targets in CTL assays with either class I-restricted CD8 1 CTL clones, or with stimulated PBMCs from an HLA-matched seropositive individual. Figure 4A shows that when B-LCLs from HLA-A3 1 vaccinees were infected with a vaccinia vector expressing the HIV-1 Env protein, they were readily lysed (27) 73 (31) control a In all experiments, stimulator cells were autologous B-LCLs that were either infected with the appropriate vac-HIV construct or pulsed with peptide(s) as described in Materials and Methods.
b HIV-1-specific lysis was calculated as the percent specific lysis of vac-HIV-infect ed or peptide-pulsed B-LCLs minus the percent specific lysis of control (vac-infected or unpulsed) targets. The E; T ratio was 50; 1.
c For all volunteers, the omission of cold target inhibitors resulted in vaccinia-specific lysis of 7.50%. These values are shown in parentheses next to the values for HIV-specific lysis. ND, Not determined. 1 Env-specific clone A42.46. vac-infected targets were used as a specificity control. The E:T ratio was 3:1. (B) Responses to an immunodominant Gag epitope. B-LCLs from HLA-A2 1 vaccine recipients were pulsed with the Gag peptide 77-85 or infected with vac-gag and then tested for susceptibility to lysis by CD8
1 Gag-specific clone 10830 at an E:T ratio of 3:1. The sequences of the peptides used in these experiments are given in Materials and Methods.
by the HLA-A3-restricted Env-specific clone A42.46. Similarly, in Fig. 4B , B-LCLs from HLA-A2 1 nonresponders were lysed by the A2-restricted, Gag-specific clone 10830 after infection with a vaccinia vector expressing HIV-1 gag. These results indicate that cells from all of the volunteers tested were able to present HIV-1 antigen to antigen-specific T cells, and that there were no apparent defects or differences in their ability to process and present HIV-1 antigens expressed in the vaccine vector.
Stimulation of vaccinee PBMCs using epitopic peptide
In light of the fact that cells from CTL nonresponders were fully capable of processing and presenting the relevant HIV-1 antigens, we examined the possibility that epitope-specific CTL responses were induced, but escaped detection by the assay methods used. To detect potentially weak, vaccine-induced CTL responses potentially missed by vaccinia-based stimulation methods, an alternate method of stimulation was evaluated. Peptide stimulation is a classic method for eliciting a secondary in vitro CTL response. Therefore, parallel experim ents were performed in which PBMCs from vaccine volunteers were stimulated with autologous B-LCLs pulsed with peptides representing immunodominant epitopes in HIV-1 proteins expressed in the vaccine vector.
Autologous B-LCLs from vaccinees were pulsed with 10 m M concentrations of epitope peptide as described in Materials and Methods. Peptides from both the Gag and Env protein of HIV-1, restricted by HLA-A2 and -A3, respectively, were used. Peptide-pulsed autologous cells were then used to stimulate fresh PBMCs from volunteers in a 10-to 14-day in vitro culture. Cultures stim ulated with B-LCLs infected with recom binant vaccinia vectors carrying the gag or env gene were used for comparison. A standard CTL assay was then performed. A representative experiment from week 78 in all volunteers is shown in Table 3 . While peptide-pulsed stimulator cells were equivalent or superior to stimulator cells infected with the vaccinia expression vectors in eliciting CTL responses from seropositive donors (Table 3) , no previously undetected CTL responses in vaccinees were observed with peptide-pulsed stimulator cells. Similar results were obtained for other vaccinees (Table 3) . As a positive control in these experiments, effectors stim ulated with cells infected with vac-HIV vectors were tested for vaccinia-specific CTL activity by omission of cold target inhibitors. In this case, vaccinia-specific lysis of . 50% was observed, indicating again that the stim ulation and assay procedures can readily detect memory CTLs. Thus, even with highly sensitive and specific stimulation procedures, CTLs specific for defined HIV-1 epitopes were not detectable in nonresponders.
Direct visualization of Gag-specific CD8 1 T cells by FACS
To confirm that CTLs specific for an immunodominant A2-restricted Gag epitope were absent in HLA-A2 1 nonresponders, a novel reagent was utilized to directly stain CD8 1 T cells with receptor specificity for the A2-restricted epitope from the p17 portion of the HIV-1 Gag protein (amino acids 77-85). This is an immunodominant CTL epitope in natural infection. The preparation and characterization of this reagent have been previously described. 48 Briefly, a chim eric HLA-A2/Ig molecule was constructed by insertion of sequences encoding the extracellular domains of HLA-A2 (a 2 -a 3 ) upstream of a rearranged immunoglobulin heavy chain, using a linker similar to that previously described for a murine H-2K b /Ig com plex. 48 The PBMCs from five seropositive volunteers and three vaccinees, all expressing HLA-A2, were analyzed for staining with the Gag-A2/Ig. The fraction of CD8 1 cells that stained with Gag-A2/Ig was determined by two-color flow cytometry. In control experim ents using PBMCs from seronegative, nonvaccinated donors, , 0.1% of CD8 1 T cells stained with Gag-A2/Ig. Therefore, a value $ 0.1% of Gag-A2/Ig 1 cells was considered positive. Control experiments for background staining levels were also performed using an HTLV-I Tax-specific clone that recognizes the A2-restricted epitope LLFGYPVYV. As shown in Fig. 5A , in one of the seropositive donors, nearly 3% of the CD8 1 T cells from fresh PBMCs were reactive with Gag-A2/Ig. PBMCs from this donor lysed autologous B-LCLs expressing the Gag protein. Expansion of Gag-specific T cells was detected in four seropositive volunteers after in vitro stimulation with Gag 77-85 peptide-pulsed B-LCLs (Table 4) .
Three of the five vaccine volunteers in this study express the A2 allele (Table 1 ; 8MW, 8MV, and 8N5). Fresh PBMCs from each of these volunteers were tested at week 78 for reactivity with Gag-A2/Ig. In addition, a non-A2 vaccine volunteer (8NO) and an A2 1 unvaccinated seronegative control were tested. In each case, no Gag-A2/Ig-reac tive cells were detected above background levels either before or after in vitro stimulation with peptide-pulsed or vac-gag-infected autologous B-LCLs (Fig. 5B  and Table 4 ; 8MU, 8MV, and 8MW). As expected, these individuals had no detectable HIV-1-specific CTLs at this time (Table 4 ). These data indicate that the level of sensitivity of the dimeric assay is adequate to detect low levels of HIV-1 antigen-specific cells. These experiments provide additional support for the conclusion that in the nonresponders, CTLs specific for an immunodominant Gag epitope were not induced.
DISCUSSION
It is likely that an efficacious AIDS vaccine will elicit both antibody and CTL responses in a majority of vaccinated individuals. Initial trials of candidate AIDS vaccines have provided considerable data on the ability of diverse vaccine strategies to induce humoral and/or cellular immune responses. [25] [26] [27] [28] [29] [30] [31] [32] [33] Several phase I and II trials using canarypox-based vectors have shown that a majority of individuals respond to these recombinant live viral vaccines and make both CD4 1 and CD8 1 CTL responses to the HIV-1 antigens expressed in the vaccine vector. Encouraging reports from Ferrari et al. and Cao et al. have shown that CTL clones generated from responses to clade B isolates through vaccination and infection can recognize clade A and E isolates. 61, 62 Nevertheless, the failure of some vaccinees to generate detectable CTL responses remains a major issue in AIDS vaccine development.
Vaccine nonresponsiveness has been intensely studied for other pathogenic human viruses such as influenza, measles, and hepatitis B. 63 While vaccine nonresponsivenes s has clearly been demonstrated in humans, the actual mechanisms of nonresponsiveness remain largely uncharacterized. Failure of vaccination to induce antigen-specific T cells raises the possibility of classic MHC-linked nonresponsivenes s. Desom bre et al. showed that the HLA-linked nonresponsivenes s in those vaccinated with hepatitis B was not due to an inability to correctly process and present hepatitis B surface antigen (HbsAg) to class I-restricted haplo-identical T cell lines in vitro. 64 Watanabe et al. described linkage disequilibrium between the HLA-Bw54-DR4-DRw53 haplotype and a nonresponsive HbsAg suppressor T cell response. 51 Interestingly, Hayney et al. described polymorphisms of the TAP gene products and measles vaccine nonresponsiveness. They identified a homozygous TAP2 position 665 genotype as significantly indicative of measles vaccine nonresponsiveness, owing likely to linkage disequilibrium with a class I allele. 65 Cell lines that are defective in antigen presentation as a result of defects in the TAP complex have been described. [66] [67] [68] The preceding studies illustrate that the determinants that influence the ability of an individual to respond to a particular vaccine are numerous and complex. These studies have examined nonresponsivenes s related to antibody production and CD4 1 T cell responsiveness. In the present study, we conducted an in-depth characterization of CD8 1 CTL responses of a subset of volunteers participating in an AIDS vaccine trial. While all volunteers tested had at least two vaccinations with an ALVAC-HIV vector, and all had detectable serum antibodies to gp120, only one of five individuals had detectable HIV-1-specific CTLs. Interestingly, this volunteer (8MU) had strong and persistent CD4 1 and CD8 1 CTLs to the Gag and Env proteins of HIV-1 at all time points tested during the trial. When this individual was tested approximately 1 year after completion of the vaccine regim en, no HIV-1-specific CTLs could be detected, indicating that this response was not durable.
To exam ine possible explanations for the differences in the ability of these individuals to mount a detectable HIV-1-specific CTL response, com parative assays were done to test for (1) the ability of their expressed HLA molecules to present known HIV-1 epitopes to CTLs from HLA-matched, seropositive donors, or cognate CD8 1 clones; (2) the ability of B-LCLs from these individuals to properly process and present HIV-1 antigens to CTLs from HLA-matched, seropositive donors or cognate CD8 1 clones; (3) the ability of the CTL assay to detect memory CTLs in these individuals to other viral pathogens, nam ely CMV and vaccinia; and (4) the ability to detect low levels of circulating HIV-1-specifi c precursor cells using epitopic peptide stimulation and flow cytometric analysis for HIV-1-specific CTLs.
Results of these experiments showed that the individuals studied in this trial had no inherent defects or differences in their ability to process and present viral antigens (Figs. 4 and  5) . Furtherm ore, detection of CMV-specific memory CTLs correlated precisely with ELISA antibody positivity in six of six individuals tested ( Table 2 ), indicating that the sensitivity of the CTL assay is adequate to detect memory responses. Two other methodologies were employed to detect low levels of precursor CTLs (pCTLs) that may have been missed by conventional assays. First, pulsing of stimulating cells with known epitopic peptides in the requisite in vitro stimulation step failed to elicit detectable CTLs in any of the vaccinees tested, while seropositive individuals had a robust response to these epitopes ( Table 3) .
The second method involved direct staining of antigen-specific T cells by using soluble-muiltiva lent, peptide-loaded class I molecules. It has been previously shown that the frequency of circulating pCTLs specific for HIV-1 antigens can range from 0.001 to 10%, depending on the individual, the assay used, and the epitopes in question. 10, 69 Conventional precursor frequency assays are performed by limiting dilution of donor PBMCs, followed by a functional CTL assay. 70 It is thought, how ever, that these measurem ents can underestimate the number of precursors by 10-to 50-fold. 69 ,71,72 using a novel reagent described by Dal Porto et al., 48 we were able to measure the num ber of CD8 1 T cells in a mixed population that were positive for receptors that recognize the A2-restricted epitope in HIV-1 Gag 77-85. For all of the vaccine volunteers tested, the level of CD8 1 Gag 77-85-specific T cells was less than 0.1% both before and after one in vitro stimulation. Similarly, none of these individuals had a detectable CTL response at the time points tested (Table 4) . Three of five seropositive volunteers tested did have detectable CD8 1 T cells specific for the immunodominan t Gag epitope from fresh PBMCs. These findings generally agreed with our ability to detect HIV-1 Gag-specific CTLs in these individuals using conventional assays (Table 4) . Furtherm ore, the frequency of detection of these cells in seropositive volunteers in the preceding experiments was similar to that seen using a functionally similar staining reagent described by Ogg et al. and Altman et al., in which HIV-1-specific T lymphocytes are stained using soluble peptide-MHC tetramers. 12, 72 Thus, assays with enhanced sensitivity for detecting HIV-1-specifi c CTLs were unable to detect CTLs in the vaccine nonresponders. An alternative explanation for these results is that the immunodom inance for the SLYNTVATL epitope seen in the CTL response from seropositive individuals may not be recapitulated by the administration of the vaccine antigen.
While this study provides a novel algorithm by which to examine vaccine CTL nonresponsiveness , it is still not clear why som e individuals in this and other AIDS vaccine trials do not mount a detectable CTL response. The present study does, however, form ally rule out MHC-linked nonresponsivenes s in these individuals. It does not rule out potential T cell repertoire defects. This possibility seems unlikely, owing to the complex nature of the vaccine and the number of HIV-1 antigens expressed. Another important issue concerns whether large, complicated vaccine vectors such as canarypox virus and vaccinia may shift the balance of HIV-1 specific CTL epitopes presented to T cells by competing for binding with the MHC class I molecules in the antigen-presenting cells in vivo.
Alternatively, sampling issues and vaccination schedules and dosages must be addressed when estimating CTL responses to candidate vaccines. Studies are underway to determ ine if volunteer PBMCs are being obtained at optimal time points (2 weeks postvaccination), and from optimal com partments (peripheral blood versus secondary lymphoid organs). Furthermore, data from subsequent AIDS vaccine trials have shown that better HIV-1-specific CTL responses can be detected after four vaccinations with 10 6 .8 TCID of ALVAC-HIV. No individuals in this study received this regimen. Finally, it is possi-ble that the first-gener ation ALVAC-HIV vectors were suboptimal in their ability to express antigen, thereby limiting their capacity to induce a long-lived CTL response. The unique aspect of the canarypox vectors is their inability to replicate in a human host. In this situation, the num ber of host cells capable of presenting the vaccine antigen is limited to the number of cells initially infected. While this is clearly a benefit for vaccine safety in humans, the same properties may reduce immunogenic ity. Several new canarypox vectors are currently being developed to boost antigen expression in infected cells and elicit a stronger response. The approach for analyses of CTL responses in vaccinees described in this study may prove useful for studying cellular immune responses in future vaccine trials.
